Scientists from the Institute of Molecular Genetics of the Czech Academy of Sciences, in collaboration with the Faculty of ...

Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast ...

Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting drugs, a hot topic in ...

Precision oncology advancements have led to new treatment options for gastric cancer, including immunotherapy and targeted ...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesophageal ...

Claudin 6 (CLDN6) is an intercellular adhesion molecule that develops tight junctions all around cells and controls epidermal permeability, restricting the free passage of solutes and water via cells.

The Claudin family proteins, including Claudin 18.2, Claudin 18.1, Claudin 6, and Claudin 9, have been introduced effectively by ACROBiosystems. These multi-pass full-length transmembrane target ...

The Claudin 18.2 test is a highly specialized diagnostic tool, offering precise identification of the Claudin 18.2 protein, a crucial biomarker for gastric, pancreatic, and other cancers. By providing ...